This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Winer A , Adams S , Mignatti P
Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes
Mol Cancer Ther. 2018 Jun;17(6) :1147-1155
PMID: 29735645 PMCID: PMC5984693 URL: https://www.ncbi.nlm.nih.gov/pubmed/29735645
AbstractThe matrix metalloproteinases (MMP) are a family of proteolytic enzymes that degrade multiple components of the extracellular matrix. A large body of experimental and clinical evidence has implicated MMPs in tumor invasion, neoangiogenesis, and metastasis, and therefore they represent ideal pharmacologic targets for cancer therapy. From the 1990s to early 2000s, synthetic inhibitors of MMPs (MMPI) were studied in various cancer types. Unexpectedly, despite strongly promising preclinical data, all trials were unsuccessful in reducing tumor burden or improving overall survival; in addition, MMPIs had unforeseen, severe side effects. Two main reasons can explain the failure of MMPIs in clinical trials. It has now become apparent that some MMPs have antitumor effects; therefore, the broad-spectrum MMPIs used in the initial trials might block these MMPs and result in tumor progression. In addition, although MMPs are involved in the early stages of tumor progression, MMPIs were tested in patients with advanced disease, beyond the stage when these compounds could be effective. As more specific MMPIs are now available, MMP targeting could be reconsidered for cancer therapy; however, new trials should be designed to test their antimetastatic properties in early-stage tumors, and endpoints should focus on parameters other than decreasing metastatic tumor burden. (C) 2018 AACR.
NotesWiner, Arthur Adams, Sylvia Mignatti, Paolo Mignatti, Paolo/0000-0002-8157-457X; Adams, Sylvia/0000-0003-4737-1952 1538-8514